U.S. markets closed
  • S&P Futures

    4,015.00
    -17.50 (-0.43%)
     
  • Dow Futures

    34,252.00
    -104.00 (-0.30%)
     
  • Nasdaq Futures

    11,723.00
    -59.75 (-0.51%)
     
  • Russell 2000 Futures

    1,861.20
    -9.00 (-0.48%)
     
  • Crude Oil

    76.06
    -0.22 (-0.29%)
     
  • Gold

    1,753.30
    -0.70 (-0.04%)
     
  • Silver

    21.32
    -0.11 (-0.51%)
     
  • EUR/USD

    1.0385
    -0.0019 (-0.19%)
     
  • 10-Yr Bond

    3.6910
    -0.0150 (-0.40%)
     
  • Vix

    20.50
    +0.08 (+0.39%)
     
  • GBP/USD

    1.2073
    -0.0017 (-0.14%)
     
  • USD/JPY

    138.9050
    -0.1950 (-0.14%)
     
  • BTC-USD

    16,476.45
    +6.73 (+0.04%)
     
  • CMC Crypto 200

    387.47
    +4.81 (+1.26%)
     
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • Nikkei 225

    28,112.59
    -170.44 (-0.60%)
     

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

Presentation to highlight oral difelikefalin Phase 3 pruritus programs

STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual research and development (R&D) event on Friday, March 11, 2022, from 1:00 to 2:00 p.m. ET. The presentation will focus on the initiation of oral difelikefalin Phase 3 programs for the treatment of pruritus in patients with atopic dermatitis and non-dialysis dependent chronic kidney disease. An interactive Q&A session will follow the presentation.

Presenters will include:

  • Christopher Posner, President & Chief Executive Officer and Director of Cara Therapeutics

  • Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics

  • Brian Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, NY

  • Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences

A live audio webcast of the presentation and accompanying slides will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the presentation.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and plans to initiate Phase 3 programs in the first quarter of 2022 for the treatment of pruritus in patients with atopic dermatitis and non-dialysis-dependent chronic kidney disease. Phase 2 trials of oral difelikefalin are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com